Abstract
Current review aims to provide an overview of objective measures for biological treatment monitoring of patients with inflammatory bowel disease. Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies to bind specifically to certain proteins or cells which is aimed to reduce inflammatory response and minimalized of tissue damage.
A monoclonal antibodies exert an interindividual variability in their efficacy and side effects and also various metabolism and clearance in patients bodies. Biological monitoring of serum drug levels and antibodies to these drugs allowing for individualized prescription and dose adjustments may lead to therapeutic optimization and reducing the cost of these expensive therapeutic modality.